Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Los Angeles, California and other locations
Dates
study started
completion around
Principal Investigator
by Zev A Wainberg

Description

Summary

To characterize safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of QEQ278 in adult patients with advanced/metastatic non-small cell lung cancer, esophageal squamous cell carcinoma, renal cell carcinoma, and human papilloma virus associated head and neck squamous cell carcinoma.

Official Title

A Phase I/Ib, Open-label, Multi-center, Study of QEQ278 in Patients With Advanced Solid Tumors

Details

This study is an open-label, phase I/Ib, multi-center study of QEQ278 as a single agent, consisting of a dose escalation part followed by a dose expansion part.

In the dose escalation part of the study, patients with non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), renal cell carcinoma (RCC), or human papilloma virus (HPV)-associated head and neck squamous cell carcinoma (HNSCC) will be treated with QEQ278 single agent until the maximum tolerated dose (MTD) is reached or a lower recommended dose (RD) is established.

The study may enter the dose expansion, after an MTD(s) and/or RD(s) is declared in the dose escalation.

Keywords

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Esophageal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, NKG2D, NKG2D-L, immunotherapy, ADCC, NK cells, NSCLC, ESCC, RCC, HPV-associated HNSCC, QEQ278, Carcinoma, Squamous Cell Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Carcinoma

Eligibility

You can join if…

Open to people ages 18 years and up

  • Signed informed consent must be obtained prior to participation in the study.
  • Adult men and women ≥ 18 years of age.
  • Histologically confirmed and documented advanced malignancies (locally advanced malignancies, non-curable by surgery or radiotherapy and metastatic disease). Disease must be measurable, including presence of at least one measurable lesion, as determined by RECIST v1.1.
  • In the opinion of the treating investigator, patients must have received, but are not benefitting from standard therapies, be intolerant or ineligible to receive such therapy, or have no standard therapy option for the respective disease types (diseases listed below), as well as any other therapies deemed to be standard by local/institutional standard.
  • Non-small cell lung cancer
  • Esophageal squamous cell carcinoma
  • Renal cell carcinoma
  • HPV-associated head and neck squamous cell carcinoma
  • Must have a site of disease amenable to biopsy and be a candidate for tumor biopsy according to the treating institution's guidelines. The patient must be willing to undergo a new tumor biopsy at screening and during treatment.

You CAN'T join if...

  • Active previously documented or suspected autoimmune disease. Patients with vitiligo, type I diabetes, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur should not be excluded. Patients previously exposed to anti-PD-1/PD-L1 treatment who are adequately treated for skin rash or with replacement therapy for endocrinopathies should not be excluded.
  • Patients with a history of or current interstitial lung disease or pneumonitis ≥ Grade 2.
  • Patients who discontinued prior anti-PD-1 therapy due to an anti-PD-1-related toxicity
  • Clinically significant cardiac disease or risk factors at screening
  • Insufficient bone marrow function at screening:
  • Infections:
  • Known history of testing positive for Human Immunodeficiency Virus infection.
  • Active Hepatitis B and / or Hepatitis C.
  • Active, documented COVID-19 infection
  • Known history of tuberculosis
  • Any serious uncontrolled infection (acute or chronic).
  • Systemic chronic steroid therapy (>10 mg/day prednisone or equivalent) or any immunosuppressive therapy, other than replacement-dose steroids in the setting of adrenal insufficiency, within 7 days of the first dose of study treatment. Topical, inhaled, and ophthalmic steroids are allowed.

Other protocol-defined inclusion/exclusion criteria may apply.

Locations

  • University Of California LA Santa Monica Location accepting new patients
    Los Angeles California 90095 United States
  • Florida Cancer Specialists Sarasota Office accepting new patients
    Fort Myers Florida 33901 United States

Lead Scientist at UCLA

  • Zev A Wainberg
    HS Clinical Professor, Medicine. Authored (or co-authored) 159 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Novartis Pharmaceuticals
ID
NCT05462873
Phase
Phase 1 research study
Study Type
Interventional
Participants
Expecting 125 study participants
Last Updated